Prokidney announces positive interim regen-007 phase 2 trial data and provides clinical and operational updates

Winston-salem, n.c., june 10, 2024 (globe newswire) --  prokidney corp. (nasdaq: prok) (“prokidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced positive interim results from the phase 2 regen-007 trial evaluating the company's renal autologous cell therapy, rilparencel, in patients with ckd caused by diabetes and provided clinical and operational updates. management will host a live webcast today at 8:00 a.m. et to discuss the data.
prok Ratings Summary
prok Quant Ranking